These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26876104)

  • 1. Long-acting follicle-stimulating hormone versus daily follicle-stimulating hormone for women undergoing assisted reproduction.
    Pouwer AW; Farquhar C; Kremer JA; Marjoribanks J
    Fertil Steril; 2016 Jun; 105(6):1454-6. PubMed ID: 26876104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation.
    Kofinas JD; Elias RT
    Womens Health (Lond); 2014 Sep; 10(5):505-9. PubMed ID: 24807379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer.
    Sarais V; Paffoni A; Pagliardini L; Filippi F; Martinelli F; Mangili G; Candiani M; Papaleo E
    Acta Obstet Gynecol Scand; 2017 Aug; 96(8):949-953. PubMed ID: 28382680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study.
    Ng EY; Yeung WS; Ho PC
    Hong Kong Med J; 2000 Dec; 6(4):368-74. PubMed ID: 11177158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
    Strowitzki T; Kuczynski W; Mueller A; Bias P
    Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles.
    La Marca A; Papaleo E; Grisendi V; Argento C; Giulini S; Volpe A
    BJOG; 2012 Sep; 119(10):1171-9. PubMed ID: 22805536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome.
    Aboulghar M; Saber W; Amin Y; Aboulghar M; Mansour R; Serour G
    Fertil Steril; 2010 Nov; 94(6):2332-4. PubMed ID: 20188364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program].
    Tsagareishvili GG; Khonelidze NL; Lazarev AP
    Georgian Med News; 2005 Jun; (123):7-12. PubMed ID: 16052045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation, characterization and application of long-acting FSH analogs for assisted reproduction.
    Ben-Menahem D
    Theriogenology; 2018 May; 112():11-17. PubMed ID: 28888334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome?
    La Marca A; Pati M; Giulini S; Levratti P; Caretto S; Volpe A
    Gynecol Endocrinol; 2005 Nov; 21(5):292-4. PubMed ID: 16373249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of daily and alternate day recombinant follicle-stimulating hormone stimulation protocols for intrauterine insemination.
    Kabli N; Sylvestre C; Tulandi T; Buckett W
    Fertil Steril; 2009 Apr; 91(4):1141-4. PubMed ID: 18342857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
    Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.